Recombinant human interferon alpha2a suppository and preparation method
A technology of recombinant human interferon and interferon α, which is applied in suppository delivery, drug combination, pharmaceutical formula, etc., can solve the problems of poor compliance of injection, protein instability, high price, etc., and achieve good antiviral effect, The production process is simple and easy, and the biological activity is stable
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0029] Preparation of recombinant human interferon α2a plug
[0030] (1) Matrix preparation and initial dissolution
[0031] Add glycerin, gelatin, and water for injection into a sterile and airtight suppository matrix tank according to the ratio of 5:2:1 to 5:3:2. Close the feed inlet valve, open the stirring switch, exhaust valve, circulating water valve and steam valve, heat the temperature to 80-90°C, and stir continuously to dissolve it, the stirring speed is 20-40 rpm;
[0032] (2) Matrix sterilization
[0033] Keep the stirring speed at 20-40 rpm. Open the main steam valve of the suppository matrix tank, open the main exhaust valve, drain the condensed water, and close the main exhaust valve; open the interlayer air intake valve of the matrix tank, open the interlayer exhaust valve, drain the interlayer condensate, and close the interlayer exhaust valve ; After the pressure in the matrix tank reaches 0.10-0.13 Mpa, open the exhaust valve in the matrix tank, drain the...
Embodiment 2
[0039] Study on Stability of Recombinant Human Interferon α2a Plug
[0040] In order to further determine the stability of the formula and preparation method of the present invention, it is judged whether the drug is stable at the storage temperature to be changed by summarizing and analyzing the test data, so as to provide a theoretical basis for the determination of product packaging, transportation, storage conditions and expiration date , and reset the expiration date of the product during the stabilization period. Three batches of recombinant human interferon α2a suppositories (production batch numbers: S20130201, S20130202, and S20130203) produced continuously in 2013 were used as the research objects, and the accelerated stability test at 36.5-37.5°C and the long-term stability test at 29-31°C were carried out respectively.
[0041] 1. Accelerated stability investigation test of recombinant human interferon α2a suppository of the present invention at 36.5-37.5°C:
[00...
Embodiment 3
[0061] Quality Control Evaluation
[0062] 1. Identification test
[0063] The result was positive by immunoblotting ("Pharmacopoeia of the People's Republic of China" (2015 edition) three general rules 3401) or immunospot method ("People's Republic of China Pharmacopoeia" (2015 edition) three general rules 3402) assay.
[0064] 2. Visual inspection
[0065] This product should be a light yellow to brown suppository, with a complete, uniform, smooth and firm appearance.
[0066] 3. The weight difference shall be determined according to the method of "Pharmacopoeia of the People's Republic of China" (2015 Edition) Three General Rules 0107), the weight difference shall be ±5% of the labeled amount, and the result is qualified.
[0067] 4. The melting time limit is determined according to the method of the third general rule 0922 of the Pharmacopoeia of the People's Republic of China (2015 edition), and it should be qualified.
[0068] 5. The PH value is measured according to ...
PUM
Login to View More Abstract
Description
Claims
Application Information
Login to View More 


